Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. More Details
Exceptional growth potential with flawless balance sheet.
Share Price & News
How has Imricor Medical Systems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IMR's weekly volatility (7%) has been stable over the past year.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: IMR exceeded the Australian Medical Equipment industry which returned 16.5% over the past year.
Return vs Market: IMR exceeded the Australian Market which returned 35.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Imricor Medical Systems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWe're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely
1 month ago | Simply Wall StCould The Imricor Medical Systems, Inc. (ASX:IMR) Ownership Structure Tell Us Something Useful?
2 months ago | Simply Wall StWhen Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?
Is Imricor Medical Systems undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMR is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: IMR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMR is overvalued based on its PB Ratio (6.6x) compared to the AU Medical Equipment industry average (6.3x).
How is Imricor Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: IMR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMR's is expected to become profitable in the next 3 years.
Revenue vs Market: IMR's revenue (53.9% per year) is forecast to grow faster than the Australian market (4.9% per year).
High Growth Revenue: IMR's revenue (53.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMR's Return on Equity is forecast to be very high in 3 years time (73.7%).
How has Imricor Medical Systems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMR is currently unprofitable.
Growing Profit Margin: IMR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMR is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.
Accelerating Growth: Unable to compare IMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31.7%).
Return on Equity
High ROE: IMR has a negative Return on Equity (-43.19%), as it is currently unprofitable.
How is Imricor Medical Systems's financial position?
Financial Position Analysis
Short Term Liabilities: IMR's short term assets ($28.9M) exceed its short term liabilities ($2.3M).
Long Term Liabilities: IMR's short term assets ($28.9M) exceed its long term liabilities ($2.5M).
Debt to Equity History and Analysis
Debt Level: IMR is debt free.
Reducing Debt: IMR had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMR has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 32.4% each year.
What is Imricor Medical Systems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Wedan (51 yo)
Mr. Steve Wedan has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has medical device experience...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD565.00K) is about average for companies of similar size in the Australian market ($USD509.07K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Experienced Management: IMR's management team is seasoned and experienced (8.8 years average tenure).
Experienced Board: IMR's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.
Imricor Medical Systems, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Imricor Medical Systems, Inc.
- Ticker: IMR
- Exchange: ASX
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$243.134m
- Shares outstanding: 125.65m
- Website: https://www.imricor.com
- Imricor Medical Systems, Inc.
- 400 Gateway Boulevard
- United States
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the U...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 08:11|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.